ES2413011T3 - Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC - Google Patents
Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC Download PDFInfo
- Publication number
- ES2413011T3 ES2413011T3 ES05706979T ES05706979T ES2413011T3 ES 2413011 T3 ES2413011 T3 ES 2413011T3 ES 05706979 T ES05706979 T ES 05706979T ES 05706979 T ES05706979 T ES 05706979T ES 2413011 T3 ES2413011 T3 ES 2413011T3
- Authority
- ES
- Spain
- Prior art keywords
- use according
- day
- copd
- glucocorticoid
- acceptable salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 22
- 239000003862 glucocorticoid Substances 0.000 title claims abstract description 16
- 239000000812 cholinergic antagonist Substances 0.000 title description 11
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title description 5
- 229940037128 systemic glucocorticoids Drugs 0.000 title description 4
- 238000011866 long-term treatment Methods 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract description 20
- 229960002714 fluticasone Drugs 0.000 claims abstract description 15
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 9
- 229960004436 budesonide Drugs 0.000 claims abstract description 9
- 229960001664 mometasone Drugs 0.000 claims abstract description 5
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 6
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 27
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 229940124630 bronchodilator Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 8
- 229940110309 tiotropium Drugs 0.000 description 8
- 230000001078 anti-cholinergic effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229960001888 ipratropium Drugs 0.000 description 4
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960000257 tiotropium bromide Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- -1 scopine ester Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195604P | 2004-02-06 | 2004-02-06 | |
| US541956P | 2004-02-06 | ||
| PCT/EP2005/000652 WO2005074918A1 (en) | 2004-02-06 | 2005-01-24 | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2413011T3 true ES2413011T3 (es) | 2013-07-15 |
Family
ID=34837533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05706979T Expired - Lifetime ES2413011T3 (es) | 2004-02-06 | 2005-01-24 | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050175548A1 (enExample) |
| EP (1) | EP1713473B1 (enExample) |
| JP (1) | JP4819699B2 (enExample) |
| CN (1) | CN100569235C (enExample) |
| AU (1) | AU2005210085B2 (enExample) |
| CA (1) | CA2551780C (enExample) |
| DK (1) | DK1713473T3 (enExample) |
| ES (1) | ES2413011T3 (enExample) |
| HR (1) | HRP20130460T1 (enExample) |
| NO (1) | NO336882B1 (enExample) |
| NZ (1) | NZ548300A (enExample) |
| PL (1) | PL1713473T3 (enExample) |
| PT (1) | PT1713473E (enExample) |
| RU (1) | RU2440813C2 (enExample) |
| SI (1) | SI1713473T1 (enExample) |
| WO (1) | WO2005074918A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| GB0523653D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| ES2389231T3 (es) * | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| WO2009142589A1 (en) * | 2008-05-20 | 2009-11-26 | Astrazeneca Ab | Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist |
| PT3111927T (pt) | 2009-05-29 | 2020-03-03 | Pearl Therapeutics Inc | Composições para administração respiratória de agentes ativos e métodos e sistemas associados |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| WO2011076843A2 (en) | 2009-12-23 | 2011-06-30 | Chiesi Farmaceutici S.P.A. | Combination therapy for copd |
| BR112012015334A2 (pt) | 2009-12-23 | 2016-03-15 | Chiesi Farma Spa | terapia combinada para doença pulmonar obstrutiva crônica |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US9896416B2 (en) * | 2012-08-09 | 2018-02-20 | Chase Parmaceuticals Corporation | Piperidinium quaternary salts |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| KR20150119468A (ko) | 2013-02-28 | 2015-10-23 | 더미라, 인코포레이티드 | 글리코피롤레이트 염 |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| TR201902687T4 (tr) | 2013-03-15 | 2019-03-21 | Pearl Therapeutics Inc | İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler. |
| BR112016014583B1 (pt) | 2013-12-30 | 2022-12-20 | Chiesi Farmaceutici S.P.A | Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição |
| EP4591936A3 (en) | 2015-03-23 | 2025-10-15 | Tianli Biotech Pty Ltd | Treatment of respiratory diseases |
| US20160310410A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| AU2017328907B2 (en) | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
| CN113260616B (zh) | 2018-11-07 | 2025-05-02 | 天莅生物技术有限公司 | 用于治疗呼吸系统疾病的新型化合物 |
| CN109498625B (zh) * | 2018-12-29 | 2021-04-16 | 温州医科大学附属第一医院 | 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法 |
| AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
| CN120360953B (zh) * | 2025-06-24 | 2025-09-05 | 成都第一制药有限公司 | 一种用于copd治疗的莨菪烷类生物碱组合物及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU220041B (hu) | 1993-07-02 | 2001-10-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
| WO1998000016A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| WO1999062720A1 (fr) | 1998-05-29 | 1999-12-09 | Citizen Watch Co., Ltd. | Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation |
| CA2338680C (en) | 1998-08-04 | 2008-10-14 | Jago Research Ag | Medicinal aerosol formulations |
| HU226164B1 (en) * | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6086914A (en) | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| US6203779B1 (en) * | 1999-03-19 | 2001-03-20 | Charlie Ricci | Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009584D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| AU2002314102A1 (en) | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| AP2003002909A0 (en) | 2001-05-25 | 2003-12-31 | Pfizer | A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases. |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| CN1422620A (zh) * | 2001-12-07 | 2003-06-11 | 中国人民解放军总装备部后勤部军事医学研究所 | 治疗氮氧化物中毒的气雾剂及其用途和制备方法 |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| CA2478974C (en) * | 2002-03-20 | 2014-12-16 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
| US7084153B2 (en) * | 2002-04-12 | 2006-08-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising steroids and a novel anticholinergic |
| DE10216429A1 (de) * | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| US20040038958A1 (en) | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| AU2003272450A1 (en) | 2002-09-13 | 2004-04-30 | C. Steven Smith | Novel composition and method for treatment of upper respiratory conditions |
| ATE384529T1 (de) | 2003-03-28 | 2008-02-15 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
| WO2004084897A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| WO2005005999A1 (en) * | 2003-07-11 | 2005-01-20 | Philips Intellectual Property & Standards Gmbh | Improved frequency determination |
| HRP20080439T3 (hr) | 2004-02-06 | 2008-10-31 | Meda Pharma Gmbh & Co. Kg | Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti |
| JP2007524698A (ja) | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | シクレソニドとグリコピロニウムとの組合せ物 |
| ES2389231T3 (es) | 2005-12-21 | 2012-10-24 | Meda Pharma Gmbh & Co. Kg | Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias |
-
2005
- 2005-01-24 NZ NZ548300A patent/NZ548300A/en not_active IP Right Cessation
- 2005-01-24 EP EP05706979A patent/EP1713473B1/en not_active Expired - Lifetime
- 2005-01-24 PT PT57069791T patent/PT1713473E/pt unknown
- 2005-01-24 CN CNB200580004060XA patent/CN100569235C/zh not_active Expired - Fee Related
- 2005-01-24 ES ES05706979T patent/ES2413011T3/es not_active Expired - Lifetime
- 2005-01-24 CA CA2551780A patent/CA2551780C/en not_active Expired - Fee Related
- 2005-01-24 SI SI200531713T patent/SI1713473T1/sl unknown
- 2005-01-24 PL PL05706979T patent/PL1713473T3/pl unknown
- 2005-01-24 WO PCT/EP2005/000652 patent/WO2005074918A1/en not_active Ceased
- 2005-01-24 JP JP2006551763A patent/JP4819699B2/ja not_active Expired - Fee Related
- 2005-01-24 DK DK05706979.1T patent/DK1713473T3/da active
- 2005-01-24 HR HRP20130460TT patent/HRP20130460T1/hr unknown
- 2005-01-24 RU RU2006132038/15A patent/RU2440813C2/ru not_active Application Discontinuation
- 2005-01-24 AU AU2005210085A patent/AU2005210085B2/en not_active Ceased
- 2005-02-07 US US11/051,468 patent/US20050175548A1/en not_active Abandoned
-
2006
- 2006-08-31 NO NO20063879A patent/NO336882B1/no not_active IP Right Cessation
-
2008
- 2008-08-11 US US12/189,598 patent/US10537550B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005074918A1 (en) | 2005-08-18 |
| CA2551780A1 (en) | 2005-08-18 |
| US20080300226A1 (en) | 2008-12-04 |
| CN1913883A (zh) | 2007-02-14 |
| AU2005210085A1 (en) | 2005-08-18 |
| RU2006132038A (ru) | 2008-03-20 |
| RU2440813C2 (ru) | 2012-01-27 |
| AU2005210085B2 (en) | 2010-06-24 |
| JP4819699B2 (ja) | 2011-11-24 |
| SI1713473T1 (sl) | 2013-06-28 |
| JP2007520508A (ja) | 2007-07-26 |
| PL1713473T3 (pl) | 2013-08-30 |
| CN100569235C (zh) | 2009-12-16 |
| EP1713473A1 (en) | 2006-10-25 |
| NZ548300A (en) | 2010-04-30 |
| CA2551780C (en) | 2013-02-26 |
| HK1098356A1 (zh) | 2007-07-20 |
| NO336882B1 (no) | 2015-11-23 |
| DK1713473T3 (da) | 2013-06-17 |
| NO20063879L (no) | 2006-11-01 |
| US10537550B2 (en) | 2020-01-21 |
| HRP20130460T1 (hr) | 2013-06-30 |
| PT1713473E (pt) | 2013-05-13 |
| US20050175548A1 (en) | 2005-08-11 |
| EP1713473B1 (en) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2413011T3 (es) | Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC | |
| JP2014516062A (ja) | ウメクリジニウム及びコルチコステロイドを含む組合せ | |
| ES2381116T3 (es) | Combinación de anticolinérgicos e inhibidores de fosfodiesterasa tipo 4 para el tratamiento de enfermedades respiratorias | |
| JP2020023537A (ja) | Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ | |
| US8258124B2 (en) | Combination medicament | |
| KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
| AU2003292120B2 (en) | New synergistic combination comprising roflumilast and formoterol | |
| KR102448406B1 (ko) | Ａｅｒｄ/천식에서 트롬복산 수용체 길항제 | |
| AU2003288169B2 (en) | Synergistic combination comprising roflumilast and (R,R) -formoterol | |
| MXPA06008938A (en) | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd | |
| HK1098356B (en) | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd | |
| HK1232788A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd |